No Data
No Data
Express News | D. Boral Capital Maintains Buy on Citius Pharmaceuticals, Maintains $9 Price Target
Citius Pharmaceuticals Analyst Ratings
8-K: Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2025 Financial Results and Provides Business Update
Citius Pharmaceuticals 1Q Rev $0.00 >CTXR
Citius Pharmaceuticals 1Q Loss/Shr $1.30 >CTXR
10-Q: Q1 2025 Earnings Report
72055196 : why pumping this